FRATES JAMES M 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Amylyx (AMLX) CFO James Frates Sells 3,557 Shares
What Happened
James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), reported an open-market sale of 3,557 shares on 2026-02-02. The shares were sold for a weighted-average price of $14.65, generating proceeds of approximately $52,097. This sale was a disposition (sale), not a purchase.
Key Details
- Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
- Transaction type: Sale (open market/private sale); total shares sold: 3,557; weighted-average price: $14.65; price range: $14.460–$14.790.
- Reported value: ~$52,097.
- Reason/footnote: Sale was automatic to cover tax withholding related to the vesting of restricted stock units (footnote F1); not at the reporting person's discretion.
- Ownership after transaction: Not specified in this Form 4.
- Additional footnotes: Shares are held in several trusts for which Frates serves as trustee or annuitant; he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest (F3–F5). Full per-price breakdown available to SEC upon request (F2).
Context
This was a routine, non-discretionary sale to satisfy tax withholding obligations on vested RSUs (a common practice), which generally does not signal a change in insider sentiment. No options were exercised and no new awards or purchases were reported in this filing.
Insider Transaction Report
Form 4
FRATES JAMES M
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-02$14.65/sh−3,557$52,097→ 173,547 total
Holdings
- 100,000(indirect: By Trust)
Common Stock
[F3] - 15,459(indirect: By Trust)
Common Stock
[F4] - 11,072(indirect: By Trust)
Common Stock
[F5]
Footnotes (5)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.460 to $14.790. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F4]Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F5]Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Signature
/s/ Joshua B. Cohen, as Attorney in Fact|2026-02-04